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Helsinki and Kuopio, Finland; Göteborg, Sweden; and Sydney, Australia
Objectives The aim of this substudy was to ascertain whether long-term treatment with fenofibrate reduces surrogate mea-
sures of atherosclerosis, biomarkers of inflammation, and endothelial activation in patients with type 2 diabetes.
Background Some fibrates may decrease cardiovascular events, improve endothelial function, and reduce levels of acute-
phase proteins. In the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study, fenofibrate failed
to decrease the primary end point of coronary events in patients with type 2 diabetes.
Methods A total of 170 patients with type 2 diabetes of the FIELD Helsinki cohort were randomly assigned to micronized
fenofibrate 200 mg/day or placebo in a double-blind design. Carotid intima-media thickness (IMT) and the aug-
mentation index (a measure of large artery stiffness) were measured at baseline and at second- and fifth-year
visits. Plasma levels of interleukin (IL)-6, C-reactive protein (CRP), serum amyloid A (SAA), secretory phospho-
lipase A2 IIA (SPLA2), E-selectin, vascular cellular adhesion molecule (VCAM)-1, and intercellular adhesion mole-
cule (CAM)-1 were determined by commercial enzyme-linked immunosorbent assay kits at the same visits.
Results IMT and the augmentation index increased similarly in both treatment groups during the study. Plasma levels of
CRP, IL-6, SPLA2, SAA, VCAM-1, ICAM-1, and E-selectin remained unchanged in both groups.
Conclusions Fenofibrate treatment was not associated with beneficial changes in IMT, augmentation index, or biomarkers of
inflammation and endothelial function. (Fenofibrate Intervention and Event Lowering in Diabetes;
NCT00132886) (J Am Coll Cardiol 2008;52:2190–7) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.049n
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sype 2 diabetes increases the risk of coronary heart disease
t least 2- to 3-fold. Patients with type 2 diabetes without
yocardial infarction (MI) have a risk for fatal MI similar to
rom the Departments of *Medicine and †Diabetes, University of Helsinki, Helsinki
niversity Central Hospital and Biomedicum, Helsinki, Finland; ‡Wallenberg
aboratory for Cardiovascular Research, Sahlgrenska University Hospital, Göteborg,
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inland; Oy Jurilab Ltd., Kuopio, Finland; and the ¶NHMRC Clinical Trials
entre, University of Sydney, Sydney, Australia. This work was supported by grants
rom the Finnish Diabetes Association (to Drs. Leinonen and Taskinen), Jenny and
ntti Wihuri Fund (to Dr. Leinonen), Helsinki University Central Hospital Research
oundation (to Drs. Hiukka, Leinonen, and Taskinen), Aarne Koskelo Foundation
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ssociation for Hiroshima University Graduate School of Biomedical Science (to Dr.
atanabe), and Sigrid Juselius Foundation (to Dr. Taskinen).t
Manuscript received June 9, 2008; revised manuscript received September 22, 2008,
ccepted September 29, 2008.ondiabetic subjects with histories of MI (1,2). Statins
ffectively reduce cardiovascular end points in type 2 diabe-
es (3). Regarding surrogate markers of atherosclerosis in
ype 2 diabetes, statins improve endothelial dysfunction
4,5) and reduce markers of endothelial activation and
nflammation (6–8), progression of intima-media thickness
9), and augmentation index (10,11).
See page 2206
Considering the abundant data on slower progression of
therosclerosis with statins, studies on fibrates are surpris-
ngly scarce. Fibrates reduced coronary heart disease events
n subjects with type 2 diabetes or metabolic syndrome in
ubgroup analyses of the VA-HIT (Veterans Administra-
ion High-density lipoprotein Intervention Trial) and BIP
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AIS (Diabetes Atherosclerosis Intervention Study), feno-
brate slowed progression of coronary atherosclerosis but
id not significantly reduce cardiac end points (14). Studies
ith carotid intima-media thickness (IMT) as a surrogate
nd point have produced inconsistent results: one with
lower progression of carotid atherosclerosis in patients on
enofibrate compared with placebo (15) and one with no
ffect of bezafibrate on IMT (16), whereas another study
eported progression of atherosclerosis in patients on differ-
nt fibrates compared with those on statins (17).
The augmentation index predicts both all-cause and
ardiovascular mortality in patients with end-stage renal
ailure (18). In a recent small study of 16 obese men, a
-month treatment with fenofibrate reduced the augmen-
ation index significantly (19). In contrast, gemfibrozil did
ot change the augmentation index in a group of 27 patients
ith chronic kidney disease (20). There are no data on the
ong-term effects of fibrates on augmentation index in type
diabetes.
Studies on fenofibrate have shown promising results
oncerning low-grade inflammation. These have been
ostly short-term studies, and only 1 included patients with
ype 2 diabetes (21). One large long-term study was
erformed with bezafibrate, but data for patients with type
diabetes were not reported separately (22). Fenofibrate has
ncreased flow-mediated endothelium-dependent vasodila-
ation in a few small studies (23–25).
In this pre-specified FIELD (Fenofibrate Intervention
nd Event Lowering in Diabetes) substudy, we examined
he effect of 5-year fenofibrate treatment on surrogate
easures of atherosclerosis, inflammation, and endothelial
ctivation in statin-free patients with type 2 diabetes. We
easured carotid IMT by ultrasound and augmentation
ndex by radial applanation tonometry and pulse-wave
nalysis. We measured low-grade inflammation by analyz-
ng plasma C-reactive protein (CRP), interleukin (IL)-6,
hospholipase A2 IIA (PLA2), and serum amyloid A
SAA) and the endothelial activation markers vascular
ellular adhesion molecule (VCAM)-1, intercellular adhe-
ion molecule (ICAM)-1, and E-selectin.
ethods
ubjects. The main FIELD study design has been de-
cribed (26). Briefly, men and women age 50 to 75 years
ith type 2 diabetes, with or without prior coronary heart
isease, were eligible using the following lipid criteria: 115
o 210 mg/dl serum-cholesterol plus either 90 to 440 mg/dl
erum-triglycerides or a serum-cholesterol/high-density li-
oprotein (HDL) cholesterol ratio 4. Subjects with he-
atic or renal dysfunction, gallstones, lipid-lowering medi-
ation, cyclosporine, alcohol overuse, or other severe mental
r physical illness were excluded. Patients received dietary
dvice designed for patients with diabetes at the first main utudy visit, and their physical ac-
ivity was recorded at baseline
nd second- and fifth-year main
tudy visits. The first substudy
atient was screened in June 1998,
nd the last substudy patient visit
as performed in March 2005.
e recruited 270 subjects with
ype 2 diabetes to the FIELD
tudy at the Helsinki Centre. Of
hese patients, 239 volunteered
o participate in this substudy,
nd 228 were randomly assigned
o receive, in a double-blind de-
ign, placebo or micronized fe-
ofibrate (200 mg/day) for 5
ears (113 vs. 115 patients, re-
pectively). At the fifth-year sub-
tudy close, the respective numbers were 99 patients in the
lacebo group and 95 in the fenofibrate group. During the
tudy, there were 2 deaths and 12 serious adverse events in
he placebo group and 5 deaths and 15 serious adverse
vents in the fenofibrate group. We excluded patients who
ad statin added to their medications during the study (16
n the placebo group vs. 8 in the fenofibrate group). After
his, 170 subjects were eligible for analysis (placebo group:
 83, men/women 62/21; fenofibrate group: n  87,
en/women 63/24). In 151 patients (placebo group: n 
5, men/women 53/22; fenofibrate group: n  76, men/
omen 55/21), pulse-wave analyses were performed. The
haracteristics of these patients did not differ from those of
he entire substudy group. Patients with plasma CRP levels
10 mg/l were excluded from the cytokine analysis. All
atients signed informed consent forms. The Ethics Com-
ittee of the Helsinki University Central Hospital approved
he substudy protocol.
aboratory analyses. The baseline examinations were per-
ormed during the placebo run-in period of the FIELD
tudy before any fenofibrate intervention. Blood samples
ere obtained after overnight fasts. Serum and ethylenedi-
minetetraacetic acid plasma were separated by centrifuga-
ion and stored at 80°C until analyzed. Commercially
vailable enzyme-linked immunosorbent assay kits were
sed to determine ICAM-1 (coefficient of variance [CV]
.4%), VCAM-1 (CV 9.2%), E-selectin (CV 7.3%), and
L-6 (CV 15.1%) (R&D Systems, Minneapolis, Minne-
ota); ultra-sensitive CRP (CV 12.8%) (Medix Biochemica,
auniainen, Finland); SAA (CV 21.9%) (Biosource Inter-
ational, Camarillo, California); and secretory phospho-
ipase A2 IIA (SPLA2) (CV 22.1%) (Cayman Chemical
ompany, Ann Arbor, Michigan). Lipids, plasma glucose,
nd glycosylated hemoglobin were measured as described
27).
easurement of carotid IMT. The method used in the
resent study has been described elsewhere (28). Briefly,
Abbreviations
and Acronyms
CRP  C-reactive protein
HDL  high-density
lipoprotein
ICAM  intercellular
adhesion molecule
IL  interleukin
IMT  intima-media
thickness
MI  myocardial infarction
SAA  serum amyloid A
SPLA2  secretory
phospholipase A2 IIA
VCAM  vascular cellular
adhesion moleculeltrasound scans were performed with a Hewlett Packard
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Arterial Effects of Fenofibrate in Type 2 Diabetes December 16/23, 2008:2190–7mage Point M2410A (Palo Alto, California) ultrasound
ystem and a 10-MHz linear array transducer and video-
aped with a Panasonic (Osaka, Japan) AG-MD830E PAL
-VHS VCR. All of the patients were scanned once at
aseline, at the second year, and at the fifth year. Both
arotid arteries were scanned from 3 projections for the
istal 1 cm of the common carotid artery and entire carotid
ulb. For the proximal 1 cm of the internal carotid artery,
he best visualized view was selected by the sonographer.
oth the far wall and near wall were measured. Computer
nalysis of the ultrasound images was performed using a PC
ith a video frame grabber interfaced to a PAL S-VHS
CR at the University of Kuopio, Kuopio, Finland. One
undred measurements per 1-cm edge length were mea-
ured with the Prosound software (Caltech, Pasadena,
alifornia).
The mean of the maximal IMT (IMT) was pre-specified
s the primary outcome variable. Secondary outcome vari-
bles were: 1) the mean of mean IMT over all scanned
arotid sites; 2) the mean of mean far-wall IMTs over all
canned carotid far-wall sites; 3) the mean of maximal IMTs
ver all scanned common carotid artery sites; 4) the mean of
aximal IMTs over all scanned carotid bulb sites; 5) the
ean of maximal IMTs for all scanned internal carotid
rtery sites; and 6) the plaque height difference between
ite-specific maximums and minimums averaged for all
canned carotid sites (plaque).
Dr. Leinonen performed the ultrasounds at baseline and
he second year, and Dr. Hiukka at the fifth year. The
ntraobserver repeatability (R) for maximal IMT was 0.994
ith a standard error of measurement errors (SE) of 0.0152
or Dr. Leinonen, and R was 0.971 with an SE of 0.029 for
r. Hiukka. The interobserver R was 0.950 and SE was
.035. The IMT scans of the patients were read by
ltrasound technicians Arja Malkki (R  0.996; SE 
.0082) and Jarmo Tiikkainen (R  0.986; SE  0.032);
haracteristics of the Patients at Baseline and After 5 Years
Table 1 Characteristics of the Patients at Baseline and After 5
Placebo (n  83)
Baseline Fifth Yea
BMI, kg/m2 29.7 (26.9–33.0) 29.5 (26.7–3
Smoking
Never 29 (35%) 29 (35%)
Ex 41 (49%) 43 (52%)
Current 13 (16%) 11 (13%)
Glucose, mg/dl 139 (117–155) 128 (108–1
HbA1c, % 7.0 (6.3–8.1) 7.0 (6.4–7.
Systolic BP, mm Hg 140 (132–150) 138 (126–1
Diastolic BP, mm Hg 88 (80–92) 80 (74–88
Serum cholesterol, mg/dl 190 (174–207) 197 (183–2
LDL cholesterol, mg/dl 118 (105–130) 128 (110–1
TG, mg/dl 147 (109–182) 134 (100–1
HDL cholesterol, mg/dl 43 (37–50) 44 (38–53
ata are median (interquartile range) and p values from repeated-measures analysis of variance. F
nd fifth year in each group are from the Wilcoxon signed-rank test for 2 related variables. *p  0.05; †
BMI  body mass index; BP  blood pressure; HbA1c  glycosylated hemoglobin; HDL  high-densityheir inter-reader R was 0.977 and SE was 0.040. Both
eaders and sonographers were blinded to the treatment
roup but not to the time sequence.
ulse-wave analyses. Pulse-wave analysis was used to de-
ermine central aortic pressures, central pressure augmenta-
ion, and the augmentation index (29). A single investigator
J.W.) used the applanation tonometry (SPC-301, Millar
nstruments, Houston, Texas) to record the pressure waves
rom the radial artery. Data were processed with the
phygmoCor Blood Pressure Analysis System (BPAS-1,
tCor Medical, Sydney, Australia). An average radial artery
aveform was calculated, and the corresponding ascending
ortic pressure waveform was generated using a validated
ransfer factor. The augmentation index was calculated by
ividing the central pressure augmentation by pulse pres-
ure. The patients had fasted overnight and they did not
ake any medication in the morning of examination.
tatistical analysis. The statistical analysis was performed
sing SPSS 11.0 for Windows (SPSS Inc., Chicago, Illi-
ois) and CIA 2.1.2 (University of Southampton School of
edicine, Hampshire, United Kingdom [30]). Results are
hown as means  standard errors of the mean or medians
nd interquartile ranges for non-normally distributed vari-
bles. We used repeated-measures analysis of variance or the
ann-Whitney U test to compare changes between the
reatment groups and Wilcoxon signed-rank test for
atched pairs to compare the changes within the groups.
reatment effect is shown with median difference of the
ercentage changes from baseline between the groups.
ualitative variables are presented as n (%), and their
hanges were compared by the 2 2 likelihood ratio test for
ransition probability matrixes (31) or Fisher exact test. We
sed linear regression analysis to calculate the individual
lopes of IMT progression or regression. A p value of0.05
as considered significant in all analyses.
rs
Fenofibrate (n  87)
p ValueBaseline Fifth Year
29.1 (26.3–32.5) 28.6 (26.3–33.4) NS
41 (47%) 41 (47%) NS
35 (40%) 35 (40%)
11 (13%) 11 (13%)
142 (122–164) 130 (130–155)* NS
7.2 (6.6–8.0) 7.3 (6.6–8.1) NS
142 (134–152) 136 (126–142)† NS
88 (82–94) 80 (74–84)† 0.047
190 (173–205 167 (146–188)† 0.001
120 (103–133) 103 (85–120)† 0.001
136 (105–190) 97 (73–148)† 0.001
45 (40–55) 44 (39–53) NS
oking,” data are n (%) and p values are based on the Fisher exact test. p values between baselineYea
r
2.9)
58)
7)
48)*
)†
21)
45)
94)
)
or “sm
p  0.001.
lipoprotein; LDL  low-density lipoprotein; TG  triglycerides.
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haracteristics of the patients. The mean age of subjects
as 61.4  6.7 years in the placebo and 62.5  6.3 years in
he fenofibrate group (p  NS). Median duration of
iabetes was 5 years (range 2 to 10 years) in the placebo
roup and 6 years (range 3 to 11 years) in the fenofibrate
roup. There was a 29% history of cardiovascular disease
ith no difference between the groups (21 in the placebo
roup and 29 in the fenofibrate group). Because of intensified
iabetes treatment, fasting serum glucose values decreased
lightly in both groups, with no change in glycosylated hemo-
lobin (Table 1, Online Table). Antihypertensive treatment
ncreased in both groups, and systolic blood pressure was
ecreased in both groups. Fenofibrate reduced total and low-
ensity lipoprotein cholesterol and triglycerides, whereas HDL
holesterol remained comparable between the treatment
roups (Table 1).
ffect of fenofibrate on IMT and the augmentation
ndex. The primary measure of IMT in our study was
aximal IMT (Fig. 1). Importantly, in both groups maxi-
al IMT was thicker at closeout than at baseline. All of the
Figure 1 Results of the Maximal and Mean IMT in
Fenofibrate and Placebo Groups During the Study
Solid circles and solid lines  fenofibrate group; open circles and dotted
lines  placebo group. Data are mean  SD. IMT  intima-media thickness.MT measures were comparable between treatment groups curing the study (Table 2). The augmentation index in-
reased in both groups (fenofibrate 27.4  0.9% vs. 30.4 
.0% [baseline vs. 5 years], p  0.0001; placebo 25.5 
.9% vs. 29.3 1.0%, p 0.005) with no significant effects
f fenofibrate (Table 3). Heart rate and central pressure
ugmentation remained unchanged in both groups after 5
ears. Similar to brachial blood pressures in the whole
ubgroup, aortic systolic and diastolic blood pressures de-
reased significantly in the fenofibrate group (Table 3).
owever, when treatment effect was analyzed using 2-way
nalysis of variance for repeated measures, there were no
ignificant effects of fenofibrate on aortic blood pressures.
ffect of fenofibrate on markers of low-grade inflamma-
ion and endothelial activation. Fenofibrate treatment did
ot change plasma levels of CRP and IL-6 in the study
roup (Table 4). In the fenofibrate group, however, women
n  23) had slightly but significantly higher plasma CRP
nd IL-6 levels compared with men (n  54) during the
tudy (data not shown). At the fifth year, plasma CRP
alues in the fenofibrate group were skewed toward higher
alues because of a nonsignificant median rise of 29.4% in
omen, whereas CRP levels in men did not change. Plasma
RP values did not differ between low- and high-risk
atients, stratified by the cut-off value of plasma CRP 2.0
g/dl (data not shown).
The PLA2 values were comparable for fenofibrate and
lacebo, despite a decrease in levels after 5 years in the
lacebo group (Table 4). Decreases in SAA levels in the
enofibrate group were not significantly different compared
ith the decrease in the placebo group. Fenofibrate had no
ffect on plasma levels of VCAM-1, ICAM-1, and
-selectin compared with those in the placebo group after 5
ears (Table 4). The plasma levels of VCAM-1, ICAM-1,
r E-selectin did not differ between sexes.
iscussion
he present study showed that long-term fenofibrate treat-
ent had no effect on carotid IMT or augmentation index
n patients with type 2 diabetes. Consistently, the markers
f low-grade inflammation and endothelial activation re-
ained unchanged. To the best of our knowledge, this is
he first long-term study to investigate the effects of feno-
brate on IMT and augmentation index in patients with
ype 2 diabetes.
Recently, regression in carotid IMT was observed with a
ombination therapy of statin and ezetimibe in patients with
ype 2 diabetes achieving aggressive low-density lipoprotein
holesterol lowering (32). IMT studies with fenofibrate are
acking in type 2 diabetic patients, but the DAIS study (14)
emonstrated a significant reduction of focal angiographic
oronary artery lesions after 3 years of fenofibrate treatment
n 418 men with type 2 diabetes. The reduction in the
rogression of mean segment diameter in coronary arteries
as not significant. Moreover, the correlation betweenoronary angiography and carotid IMT is only moderate
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Arterial Effects of Fenofibrate in Type 2 Diabetes December 16/23, 2008:2190–733). In a Japanese study of 594 hypertensive nondiabetic
atients, fenofibrate slowed the progression of IMT/arterial
iameter ratio, although the mean IMT did not change
15). A nonrandomized observational study demonstrated a
ipid-independent effect toward greater IMT and steeper
MT progression in patients on different fibrates (n  82)
ompared with those on statins (n  291) (17). In the
resent study, we observed no difference between placebo
nd fenofibrate treatment on carotid IMT during the 5-year
tudy. It is also noteworthy that a similar progression of
MT parameters over time was observed in both groups.
Augmentation index is associated with cardiovascular
orbidity and mortality in patients with type 2 diabetes
34). The present study is the first to examine the long-term
ffect of a fibrate on augmentation index in a study powered
esults of Carotid IMT Analysis at Baseline and After 5 Years
Table 2 Results of Carotid IMT Analysis at Baseline and After
IMT Baseline Second Year
Mean, mm
Placebo 1.01 (0.89–1.15) 1.03† (0.92–1.16)
Fenofibrate 1.03 (0.95–1.14) 1.03 (0.95–1.17)
Max, mm
Placebo 1.29 (1.12–1.43) 1.30* (1.18–1.46)
Fenofibrate 1.30 (1.20–1.48) 1.31 (1.20–1.50)
Far wall, mm
Placebo 1.01 (0.87–1.11) 1.04† (0.91–1.16)
Fenofibrate 1.02 (0.90–1.17) 1.03 (0.90–1.22)
Plaque, mm
Placebo 0.54 (0.47–0.63) 0.56‡ (0.48–0.63)
Fenofibrate 0.55 (0.49–0.65) 0.57‡ (0.49–0.67)
CCA, mm
Placebo 1.14 (0.99–1.30) 1.17 (0.99–0.30)
Fenofibrate 1.21 (1.09–1.31) 1.19 (1.06–1.29)
CB, mm
Placebo 1.45 (1.20–1.67) 1.51† (1.30–1.74)
Fenofibrate 1.45 (1.27–1.68) 1.51‡ (1.26–1.73)
ICA, mm
Placebo 1.12 (0.96–1.31) 1.13 (1.01–1.35)
Fenofibrate 1.12 (1.01–1.32) 1.15† (1.01–1.41)
ata are median (interquartile range) for annual changemedian (95% confidence intervals). p value
aseline and second year or fifth year in each group are from the Wilcoxon signed-rank test for 2
CB  carotid bulb; CCA  common carotid artery; ICA  internal carotid artery; IMT  intima-m
Results of Pulse-Wave Analysis at Baseline and
Table 3 Results of Pulse-Wave Analysis at B
Variable
Placeb
Baseline
Aortic systolic BP, mm Hg 136 18
Aortic diastolic BP, mm Hg 81 11
Aortic mean arterial BP, mm Hg 105 13
Aortic pulse pressure, mm Hg 55 14
Heart rate, beats/min 67 9
Augmentation, mm Hg 15 7
Augmentation index, % 26 8
There were no significant treatment effects when 2-way analysis of va
for fifth year versus baseline; †p  0.01 for fifth year versus baseline.
BP  blood pressure.y a sufficient number of patients. A few smaller short-term
tudies have been published. The effect of either gemfibrozil
r atorvastatin was compared with placebo in a 6-week
ouble-blind randomized study in patients with chronic
idney disease (n  101) (20). Approximately 20% of the
atients had diabetes. No significant changes were seen in
ither endothelial function or large artery stiffness, consis-
ent with our present study. In another small study of 16
ondiabetic obese men, 3-month treatment with fenofibrate
ignificantly reduced the augmentation index, although no
hanges in blood pressure were detected (19). Interestingly,
significant decrease in plasma ICAM- and VCAM-1
evels were also demonstrated, which may reflect the de-
ected changes. In the present study, neither a reduction in
ndothelial markers nor a decrease in augmentation index
rs
Fifth Year
Rate of Change (mm/yr)
(95% Confidence Interval) p Value
1.03† (0.91–1.17) 0.069 (0.0059 to 0.0149) 0.987
1.05† (0.96–1.19) 0.054 (0.0028 to 0.0177)
1.33* (1.17–1.47) 0.140 (0.0029 to 0.0245) 0.722
1.35* (1.24–1.53) 0.098 (0.000 to 0.0267)
1.01‡ (0.88–1.14) 0.0033 (0.0093 to 0.0148) 0.763
1.04 (0.91–1.22) 0.0035 (0.0099 to 0.0170)
0.58* (0.51–0.67) 0.0111 (0.0031 to 0.0283) 0.633
0.61* (0.52–0.71) 0.0091 (0.0032 to 0.0281)
1.19‡ (1.03–1.29) 0.0069 (0.0087 to 0.0185) 0.858
1.22† (1.13–1.32) 0.0050 (0.0051 to 0.0177)
1.51* (1.28–1.73) 0.0162 (0.0064 to 0.0419) 0.870
1.51* (1.37–1.74) 0.0141 (0.0039 to 0.0378)
1.18† (1.05–1.48) 0.0197 (0.0171 to 0.0587) 0.966
1.22† (1.02–1.45) 0.0167 (0.0154 to 0.0601)
om the Mann-Whitney U test, comparing the annual change between the groups. p values between
variables. *p  0.001; †p  0.01; ‡p  0.05.
ickness.
r 5 Years
ine and After 5 Years
75) Fenofibrate (n  76)
Fifth Year Baseline Fifth Year
132 16 136 17 129 14*
81 9 81 9 78 9†
102 10 105 11 99 10*
51 14 55 16 51 14†
67 9 68 11 65 12†
16 7 16 8 16 7
29 8† 27 8 30 9*
or repeated measures was used. Data are means  SD. *p  0.0015 Yea
s are frAfte
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similar progression of augmentation index was shown in
oth the fenofibrate and placebo groups.
Previously fibrates have been shown to reduce inflamma-
ory markers in short-term studies, but data from studies of
onger duration are scarce. The biomarkers of endothelial
ysfunction, namely ICAM-1, VCAM-1, and E-selectin,
ecrease with fenofibrate intervention (23,35); however, in a
ecent 6-week study by Hogue et al. (36), fenofibrate
ecreased only plasma E-selectin levels but not ICAM-1,
CAM-1, or CRP levels. In other short-term studies,
enofibrate treatment was reported to reduce plasma CRP
evels, along with its upstream regulator IL-6 (7,15,21,
4,25). Fenofibrate reduced CRP levels in patients with
ixed hyperlipidemia in a 60-week trial, although data from
atients with type 2 diabetes were not reported separately
21). Notably, the response to fibrates may differ between
ubjects with and without diabetes, which is the case for
lasma HDL cholesterol (12). Contrary to these short-term
ndings, here we reported that fibrate treatment did not
ignificantly alter circulating cytokine levels. This is consis-
ent with the 6-year BIP study, which showed that long-
erm bezafibrate treatment did not reduce plasma CRP
evels (22).
tudy limitations. The present study was limited by the
elatively small size of the study cohort. However, 2 distinct
Biomarkers of Inflammation and Endothelial Fun
Table 4 Biomarkers of Inflammation and En
Baseline Fifth
VCAM-1, ng/ml
Placebo 561 (434–668) 627* (53
Fenofibrate 558 (432–641) 697* (56
ICAM-1, ng/ml
Placebo 264 (222–308) 256‡ (21
Fenofibrate 256 (224–306) 244‡ (20
E-selectin, ng/ml
Placebo 56 (42–75) 49* (35
Fenofibrate 54 (43–72) 43* (33
CRP, mg/l
Placebo 1.7 (1.0–3.6) 1.6 (0.
Fenofibrate 1.8 (1.0–4.0) 2.5 (0.
SPLA, ng/ml
Placebo 3.1 (2.1–5.3) 2.4* (1.
Fenofibrate 2.7 (1.8–4.5) 2.9 (1.
IL-6, pg/ml
Placebo 2.6 (1.7–3.8) 2.5 (1.
Fenofibrate 2.3 (1.7–3.6) 2.7 (1.
SAA, g/ml
Placebo 21 (13–45) 20‡ (14
Fenofibrate 25 (15–38) 17* (13
Data are median (interquartile range) and treatment effect as median
are from the Mann-Whitney U test, comparing the relative changes fro
fifth year in each group are from the Wilcoxon signed-rank test for 2 re
†p  0.01; ‡p  0.05.
CRP C-reactive protein; ICAM intercellular adhesion molecule; IL
IIA; VCAM  vascular cellular adhesion molecule.urrogate markers of atherosclerosis (i.e., IMT and the cugmentation index) showed similar progression in both
roups with no significant effect of fenofibrate. Relatively
igh baseline IMT (37) and a study population with no
rior lipid medication should have facilitated the appearance
f significant treatment effect. Systolic blood pressure was
lightly lower in the fenofibrate treatment group, which was
lso observed in the main FIELD study. Use of beta-
lockers was more common, and the use of nitrates in-
reased more in the fenofibrate treatment group. Also, the
eduction in fasting glucose was significant only in the
enofibrate group. In a small study sample, the effect of
eparate medications to the results cannot be speculated.
onclusions
ur findings indicate that long-term fenofibrate treatment
as no effect on low-grade inflammation, endothelial acti-
ation, augmentation index, or progression of carotid IMT
n patients with type 2 diabetes. The natural progression of
therosclerosis was validated by our IMT and augmentation
ndex results. The outcomes of fibrate trials have been
ixed. The FIELD study, the largest fibrate study so far,
ielded a nonsignificant 11% reduction in coronary heart
isease events (38). This was less than expected compared
ith other fibrate studies such as VA-HIT and BIP (12,13).
hus, in patients with type 2 diabetes and prior cardiovas-
at Baseline and at 5 Years
lial Function at Baseline and at 5 Years
Median Difference of Change
(95% Confidence Interval) p Value
6) 5.6% (4.5 to16.2) 0.271
4)
0) 1.1% (7.1 to5.5) 0.761
9)
4.4% (12.8 to4.5) 0.325
20.1% (3.4 to45.0) 0.101
13.6% (0.8 to28.0) 0.064
0.8% (19.2 to22.5) 0.946
12.0% (27.9 to3.6) 0.123
ce of change between the groups (95% confidence intervals). p values
line to fifth year between the groups. p values between baseline and
ariables. n  73 for placebo and n  77 for fenofibrate. *p  0.001;
rleukin; SAA serum amyloid A; SPLA secretory phospholipase A2ction
dothe
Year
4–78
8–87
6–29
8–29
–59)
–53)
8–3.5)
8–4.8)
7–4.0)
8–3.9)
6–3.9)
9–4.1)
–28)
–23)
differen
m base
lated vular disease, fenofibrate should only be used to treat severe
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enofibrate and statin beneficially influences cardiovascular
isease end points will be answered by the ongoing AC-
ORD (Action to Control Cardiovascular Risk in Diabe-
es) study.
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APPENDIX
or a supplementary table on the medication at baseline
nd at 5 years, please see the online version of this article.
